By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem to play leading role at Boulder Peptide Symposium 2022
Bubendorf, Switzerland: –Peptide and Oligonucleotide technology specialist Bachem AG will be a prominent presence as the leading (platinum) sponsor of the Boulder Peptide Symposium in Colorado, USA.
Bachem will present its extensive portfolio of peptide and oligonucleotide products and capabilities from its stand at Booth 9 in the exhibition zone at Boulder’s St Julien spa resort and will also contribute to the four day conference agenda.
Thiazine as linker
On the afternoon of Day Three (Wednesday, November 9, 1650 hrs), Matteo Villain, Bachem’s Vice President of CMC Development, will deliver the day’s sponsored presentation on innovative application of Thiazine as ‘A new linker for peptide Bioconjugation’.
This will be followed by a CEO roundtable session chaired by Bachem AG CEO, Thomas Meier.
Partner for Tides
Bachem will also host the Speakers Dinner on the first evening of the Symposium (Monday, November 7, 1930 hrs.).
The Bachem team at the BPS will also include Chris McGee, Vice President & Head Global Business Development.
Bachem’s focus throughout the event will be on emphasising its credentials as the leading partner for ‘tides for the international life sciences industry and its team will be active in networking within the peptide community gathered at Boulder.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Further information at: www.bachem.com
About BPS 2022
Founded in 2012, the annual Boulder Peptide Symposium (BPS) is the only conference solely focused on the pharmaceutical development of peptide therapeutics.
BPS 2022 is a four-day event opening November 7 at the St Julien Hotel and Spa, in Boulder, Colorado.
BPS LIVE, featuring a full program of presentations, workshops and poster sessions, is accompanied by Virtual BPS, an online platform for short, educational talk sessions that bring the latest in peptide research and clinical development to the scientific community.
The event is organised by the Boulder Peptide Foundation with further information at: www.boulderpeptide.org.